Table 3.

Association between patient and treatment characteristics and mortality in U.S. Veterans treated for mCRPC.

Variable	All Veterans n = 5822		Veterans with cardiovascular disease or diabetes n = 4207
	aHRa	95% CI	aHRa	95% CI
Enzalutamide vs. Abiraterone	0.89	0.84–0.95	0.87	0.81–0.93
Age (per year increase)	1.02	1.01–1.02	1.01	1.01–1.02
Charlson Comorbidity Index, per point	1.05	1.04–1.06	1.04	1.03–1.06
Race: Non-black	Ref		Ref
Black	0.75	0.70–0.80	0.76	0.70–0.83
PSA Category: 0–4	Ref		Ref
4–10	1.18	1.03–1.36	1.18	1.01–1.39
10–20	1.46	1.28–1.67	1.37	1.18–1.60
20–50	1.63	1.44–1.84	1.52	1.32–1.76
50–100	2.12	1.86–2.41	2.05	1.76–2.38
100–200	2.38	2.07–2.74	2.23	1.90–2.63
200 +	2.80	2.45–3.20	2.84	2.42–3.32
unknown	2.08	1.75–2.47	1.85	1.50–2.27
Prior docetaxel	1.36	1.23–1.50	1.28	1.14–1.43
Prior bone-directed therapy	0.91	0.84–0.99	0.78	0.68–0.91
Bone-directed therapy after	1.17	1.09–1.25
BMI Category: < 18.5	1.63	1.34–1.99	1.49	1.19–1.87
18.5 ≤ BMI < 25	Ref	0.72–0.84	Ref	0.73–0.87
25 ≤ BMI < 30	0.78	0.62–0.73	0.79	0.60–0.72
BMI ≥ 30	0.70	0.74–0.93	0.66	0.69–0.91
BMI unknown	0.83		0.79
Hemoglobin: Hgb ≥ 10.0 g/dL	Ref		Ref
Hgb < 10 g/dL	1.83	1.66–2.02	1.73	1.55–1.94
unknown	0.87	0.76–1.00	0.87	0.74–1.03
eGFR: ≥ 30 ml/min	Ref		Ref
< 30	1.08	0.93–1.25	1.03	0.88–1.21
unknown	1.01	0.82–1.24	1.07	0.84–1.37
Bilirubin: <2 mg/dL	Ref		Ref
≥ 2 mg/dL	1.94	1.12–3.34	1.43	0.71–2.86
unknown	1.03	0.89–1.18	1.08	0.92–1.26
Albumin: > 3.0 g/dL	Ref		Ref
≤ 3.0 g/dL	1.85	1.61–2.13	1.88	1.64–2.15
unknown	1.10	0.97–1.25	1.15	0.99–1.32

^aaHR Adjusted Hazard Ratio from Cox proportional hazard model. Variables include: Use of abiraterone vs. enzalutamide, Age, Charlson Comorbidity index Race (black vs. non-black), baseline, PSA Prior treatment with docetaxel, treatment with bone directed therapy (zoledronic acid or denosumab), treatment with bone-directed therapy after ARTA (time varying), BMI, baseline hemoglobin (hgb), eGFR, bilirubin, albumin.